Lekovi protiv gojaznosti – razlika između verzija
Uklonjeni sadržaj Dodani sadržaj
Nova stranica: thumb|right|[[Orlistat (Xenical), često korišćeni lek za tretiranje gojaznosti, i sibutramin (Meridia) koji je nedavno povučen sa tržišta... |
m fixing dead links |
||
Red 3:
'''Lekovi protiv gojaznosti''' ili lekovi za gubljenje telesne težine su [[farmakologija|farmakološki]] agensi koji redukuju ili kontrolišu [[Telesna težina|telesnu težinu]]. Ovi [[lek]]ovi menjaju jedan od fundamentalinh procesa [[anatomija|ljudskog tela]], regulaciju težine, putem promene [[apetit]]a ili apsorpcije kalorija.<ref name=NICECG043>{{NICE|43|Obesity: The prevention, identification, assessment and management of overweight and obesity in adults and children|2006}}</ref> Glavni načini tretmana [[prekomerna težina|prekomerne težine]] i [[gojaznost]]i su i dalje [[dijeta]] i [[fizičko vežbanje]].
FDA je do sada odobrila za dugotrajnu upotrebu samo jedan lek protiv gojaznosti, [[orlistat]] (Xenical).<ref name=Meds2009>{{cite web|url=http://win.niddk.nih.gov/publications/prescription.htm#fdameds |title=WIN – Publication – Prescription Medications for the Treatment of Obesity |publisher=National Institutes of Health|work=National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |accessdate = 14. 1. 2009.| archiveurl= http://web.archive.org/web/20090113185440/http://win.niddk.nih.gov/publications/prescription.htm| archivedate = 13. 1. 2009.| deadurl= no}}</ref><ref name=Meridia2010>{{cite web |url=http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm |title=www.fda.gov}}</ref> On umanjuje intestinalnu apsorpciju masti putem inhibiranja pankreasne [[lipaza|lipaze]]. [[Rimonabant]] (Acomplia), jedan drugi lek, deluje putem specifične blokade [[kanabinoid|endokanabinoidnog]] sistema. On je razvijen polazeći od činjenice da pušači [[kanabis (lek)|kanabisa]] često osećaju glad. Taj lek je bio odobren u Evropi za tretman gojaznosti, međutim iz bezbednosnih razloga nije odobren u SAD i Kanadi.<ref>{{cite web |url=http://www.cbc.ca/health/story/2007/01/02/rimonabant.html |title=Anti-obesity drug no magic bullet |accessdate = 19. 9. 2008. |publisher=Canadian Broadcasting Corporation|date = 2. 1. 2007.|archiveurl=http://web.archive.org/web/20070105045921/http://www.cbc.ca/health/story/2007/01/02/rimonabant.html|archivedate=2007-01-05}}</ref><ref>{{cite web |url=http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf |format=PDF |title=FDA Briefing Document NDA 21-888 Zimulti (rimonabant) Tablets, 20 mg Sanofi Aventis Advisory Committee |accessdate = 19. 9. 2008. |publisher=[[Administracija za hranu i lekove|Food and Drug Administration]] |date = 13. 6. 2007.| archiveurl= http://web.archive.org/web/20080910035543/http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf| archivedate = 10. 9. 2008. | deadurl= no}}</ref> [[Evropska medicinska agencija]] je oktobra 2008 preporučila suspenziju prodaje rimonabanta jer je zaključeno da rizici nadmašuju korist.<ref>{{cite web |url=http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf |title=www.emea.europa.eu}}</ref> [[Sibutramin]] (Meridia) deluje putem inhibicije deaktivacije [[neurotransmiter]]a u mozgu, čime se umanjuje apetit. Taj lek je povučen sa tržišta u SAD i Kanadi oktobra 2010 zbog mogućih kardiovaskularnih problema.<ref name=Meridia2010/><ref>{{cite web|url=http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2010/2010_169-eng.php |title=Abbott Laboratories Voluntarily Withdraws Weight-loss Drug Sibutramine (Meridia) from the Canadian Market – Health Canada Information Update 2010-10-08}}</ref>
Zbog potencijalnih [[kontraindikacija|nuspojava]], preporučuje se da se lekovi protiv gojaznosti propisuju samo u slučajevima kada se smatra da korist nadmašuje rizike.<ref name=pmid15809464>{{cite journal|author=Snow V, Barry P, Fitterman N, Qaseem A, Weiss K |title=Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians |journal=Ann. Intern. Med. |volume=142 |issue=7 |pages=525–31 |year=2005 |pmid=15809464 |url=http://www.annals.org/cgi/content/full/142/7/525}}</ref><ref name=pmid17080028>{{cite journal |author=Cooke D, Bloom S |title=The obesity pipeline: current strategies in the development of anti-obesity drugs |journal=Nature reviews. Drug discovery |volume=5 |issue=11 |pages=919–31 |year=2006 |pmid=17080028 |doi=10.1038/nrd2136 |url=http://www.nature.com/nrd/journal/v5/n11/abs/nrd2136.html}}</ref>
| |||
